Piccin Andrea, Allameddine Allameddine, Spizzo Gilbert, Lappin Katrina M, Prati Daniele
Northern Ireland Blood Transfusion Service (NIBTS), Belfast BT9 7TS, UK.
Department of Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria.
J Clin Med. 2024 Sep 10;13(18):5359. doi: 10.3390/jcm13185359.
The recent COVID-19 pandemic has significantly challenged blood transfusion services (BTS) for providing blood products and for keeping blood supplies available. The possibility that a similar pandemic event may occur again has induced researchers and transfusionists to investigate the adoption of new tools to prevent and reduce these risks. Similarly, increased donor travelling and globalization, with consequent donor deferral and donor pool reduction, have contributed to raising awareness on this topic. Although recent studies have validated the use of pathogen reduction technology (PRT) for the control of transfusion-transmitted infections (TTI) this method is not a standard of care despite increasing adoption. We present a critical commentary on the role of PRT for platelets and on associated problems for blood transfusion services (BTS). The balance of the cost effectiveness of adopting PRT is also discussed.
近期的新冠疫情给输血服务（BTS）在提供血液制品和维持血液供应方面带来了巨大挑战。类似的大流行事件可能再次发生的可能性促使研究人员和输血工作者去研究采用新工具来预防和降低这些风险。同样，捐赠者出行增加和全球化导致捐赠者延期献血以及献血者群体减少，也促使人们对这一话题的关注度不断提高。尽管近期的研究已经证实了使用病原体灭活技术（PRT）来控制输血传播感染（TTI），但尽管其应用日益广泛，该方法仍未成为标准治疗手段。我们对PRT在血小板方面的作用以及输血服务（BTS）相关问题进行了批判性评论。同时也讨论了采用PRT的成本效益平衡问题。
